OB-318

N/A

Report date: 2022/07/08 16:38:41
NME

Base Information

Drug NameOB-318
Drug Alias NameOB-318
ClassificationNatural product/ExtractSmall molecules
Mechanisms of ActionPhosphatidylinositol 3 kinase alpha inhibitorsSerine/threonine-protein kinase mTOR inhibitorsVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor APhosphatidylinositol 3 kinase alphaSerine/threonine-protein kinase mTOR
Therapy Area/IndicationsSolid tumoursCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesOneness Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOneness Biotech Co LtdMicrobio(shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipedia